Kymera Therapeutics

positive negative up down good bad mixed
Biotech

Kymera suffers Sanofi setback but secures $750M Gilead deal

Sanofi is pulling back from its lead IRAK4 degrader, switching to a preclinical prospect, while Gilead has inked an oncology deal with Kymera.
Nick Paul Taylor Jun 25, 2025 9:31am
pivot change turnaround direction walk away

Kymera pivots to immunology, seeks partners for cancer assets

Nov 1, 2024 11:46am
try again dead end retry restart again second attempt blocked new plan

Kymera cuts lymphoma med that performed as expected in phase 1

Nov 2, 2023 9:30am
parachute skydiving

Former Arena CEO takes over new RNA biotech—Chutes & Ladders

May 26, 2023 9:30am
Sanofi of France

Sanofi backs protein degrader after glimpse of clinical efficacy

Dec 14, 2022 7:00am
A closeup of a stock market ticker

Earnings arrive after dreadful 6 months, but readouts offer hope

Jul 18, 2022 9:42am